539 results on '"Ratain, M J"'
Search Results
2. Principles of Cancer Chemotherapy
3. Disease–Drug Database for Pharmacogenomic-Based Prescribing
4. Establishment of CYP2D6 reference samples by multiple validated genotyping platforms
5. Polygenic inheritance of paclitaxel-induced sensory peripheral neuropathy driven by axon outgrowth gene sets in CALGB 40101 (Alliance)
6. The Outlier in All of Us: Why Implementing Pharmacogenomics Could Matter for Everyone
7. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing
8. Functional characterization of ABCC2 promoter polymorphisms and allele-specific expression
9. Meaningful Use of Pharmacogenetics
10. Sorafenib Dose Escalation Is Not Uniformly Associated With Blood Pressure Elevations in Normotensive Patients With Advanced Malignancies
11. Conventional Dosing of Anticancer Agents: Precisely Wrong or Just Inaccurate?
12. Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans
13. Hepatocyte nuclear factor-1 alpha is associated with UGT1A1, UGT1A9 and UGT2B7 mRNA expression in human liver
14. Challenges in Interpreting the Evidence for Genetic Predictors of Ototoxicity
15. Are Drug Labels Static or Dynamic?
16. CYP2D6 Genotype and Tamoxifen Activity: Understanding Interstudy Variability in Methodological Quality
17. Estimation of Renal Cell Carcinoma Treatment Effects From Disease Progression Modeling
18. Playing Russian Roulette With Tyrosine Kinase Inhibitors
19. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity
20. Models of Excellence: Improving Oncology Drug Development
21. The 1200 Patients Project: Creating a New Medical Model System for Clinical Implementation of Pharmacogenomics
22. Biomarkers in Early Cancer Drug Development: Limited Utility
23. Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital
24. Determination of vinca alkaloids in human plasma by liquid chromatography/atmospheric pressure chemical ionization mass spectrometry
25. Pharmacogenetic Pathway Analysis of Irinotecan
26. Nonprofit Biomedical Companies
27. Rapamycin: Something Old, Something New, Sometimes Borrowed and Now Renewed
28. The Pharmacogenetics Research Network: From SNP Discovery to Clinical Drug Response
29. Personalized Medicine: Building the GPS to Take Us There
30. Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor
31. A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors
32. A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine
33. Cancer Chemotherapy
34. A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863
35. Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction
36. Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumors
37. Phase I Study of ZD9331 on Short Daily Intravenous Bolus Infusion for 5 Days Every 3 Weeks With Fixed Dosing Recommendations
38. EPIRUBICIN IS GLUCURONIDATED BY UGT2B7.
39. HIGH VARIABILITY IN SN-38 GLUCURONIDATION IN LIVER SAMPLES FROM AFRICAN POPULATION AS PREDICTED BY UGT1A1 GENOTYPES
40. TWO NEW ALLELES IN THE PROMOTER OF THE BILIRUBIN UDP-GLUCURONOSYL TRANSFERASE 1 (UGT1A1) GENE
41. CORRELATION OF UGT1A1 GENOTYPE VERSUS SN-38 AND BILIRUBIN GLUCURONIDATION IN HUMAN LIVER SAMPLES
42. PHASE I AND PHARMACOKINETIC STUDY OF IRINOTECAN (CPT-11) ADMINISTERED WITH CYCLOSPORINE A (CSA)
43. IN VITRO GLUCURONIDATION OF FLAVOPIRIDOL (NSC649890) (FLAVO) BY HUMAN LIVER MICROSOMES
44. Genetic Basis for the Glucuronidation of SN-38: Role of UGT*1 Isoform: OI-B-1
45. Pharmacokinetic-Pharmacodynamic (PK-PD) Analysis of Intestinal Toxicity Associated with Irinotecan (CPT-11): Validation of Biliary Index (BI): PIII-38
46. Fostriecin Nephrotoxicity: An In Vitro Assessment: PII-8
47. Use in Hairy Cell Leukemia. An Update
48. ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia
49. Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study
50. ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.